Carisma Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Carisma Therapeutics's estimated annual revenue is currently $28.1M per year.
- Carisma Therapeutics's estimated revenue per employee is $407,156
- Carisma Therapeutics's total funding is $121M.
Employee Data
- Carisma Therapeutics has 69 Employees.
- Carisma Therapeutics grew their employee count by -46% last year.
Carisma Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | President and CEO | Reveal Email/Phone |
2 | Chief Medical Officer | Reveal Email/Phone |
3 | Chief Medical Officer | Reveal Email/Phone |
4 | Interim VP Finance | Reveal Email/Phone |
5 | VP, Scientific Operations | Reveal Email/Phone |
6 | VP, Discovery and Translational Science | Reveal Email/Phone |
7 | VP, Program and Portfolio Management | Reveal Email/Phone |
8 | VP, Clinical Development | Reveal Email/Phone |
9 | SVP Human Resources | Reveal Email/Phone |
10 | General Counsel and Corporate Secretary | Reveal Email/Phone |
Carisma Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $1.6M | 10 | 0% | N/A | N/A |
#2 | $4M | 26 | 13% | N/A | N/A |
#3 | N/A | 76 | 27% | N/A | N/A |
#4 | $0.9M | 6 | -14% | N/A | N/A |
#5 | $1.1M | 7 | 0% | N/A | N/A |
#6 | $10.9M | 70 | 3% | N/A | N/A |
#7 | $0.7M | 9 | 29% | N/A | N/A |
#8 | $4M | 26 | -16% | N/A | N/A |
#9 | $1.7M | 11 | 22% | N/A | N/A |
#10 | $7.6M | 49 | 2% | N/A | N/A |
What Is Carisma Therapeutics?
Carisma Therapeutics is pioneering the development of CAR macrophages, a disruptive approach to immunotherapy. Our technology leverages advances in macrophage biology, chimeric antigen receptor engineering and adoptive cellular therapy for the treatment of human disease.
keywords:N/A$121M
Total Funding
69
Number of Employees
$28.1M
Revenue (est)
-46%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Carisma Therapeutics News
Carisma Therapeutics to Present Engineered Cell Therapy Data at The American Association for Cancer Research Annual Meeting ... (PRNewsfoto/...
Carisma (www.carismatx.com ) is a biopharmaceutical company dedicated to developing a differentiated and proprietary cell therapy platform...
PHILADELPHIA, April 9, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced study findings accepted for virtual presentation at The American Association for Cancer Research (AACR) ...
PHILADELPHIA, March 18, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a clinical stage biopharmaceutical company spun out of the University of Pennsylvania (Penn) and focused on discovering and developing innovative immunotherapies, announced that the first patient has been dosed in the Phas ...
PHILADELPHIA, March 1, 2021 /PRNewswire/ -- CARISMA Therapeutics Inc., a biopharmaceutical company focused on discovering and developing innovative immunotherapies, announced today the second closing of its Series B equity financing, bringing the total amount raised in this round to $59 millio ...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $7.5M | 69 | 8% | N/A |
#2 | $14.1M | 69 | 1% | N/A |
#3 | $10.8M | 69 | 17% | $37M |
#4 | N/A | 69 | 1% | N/A |
#5 | $3.5M | 69 | 8% | N/A |